Literature DB >> 18951581

Optimal parameters for the destruction of prostate cancer using irreversible electroporation.

Jonathan Rubinsky1, Gary Onik, Paul Mikus, Boris Rubinsky.   

Abstract

PURPOSE: Irreversible electroporation is a new tissue ablation technique that consists of applying musecond pulses of direct current to create permanent defects in the cell membrane. Irreversible electroporation spares connective tissue in blood vessels and other tissue structures. When applied properly, it does not produce thermal damage. We determined the irreversible electroporation parameters that would reliably destroy prostate cancer cells.
MATERIALS AND METHODS: Irreversible electroporation pulses were applied to prostate adenocarcinoma cells in vitro. Three sets of studies were performed to determine the number, length and field strength of irreversible electroporation pulses required to produce complete cancer cell ablation without inducing thermal effects. The outcome of a treatment protocol was simulated.
RESULTS: We found the upper and lower limit bounds of pulse length and number in a field range of 2,000 to 250 V/cm. A total of 90 pulses at 250 V/cm for 100 museconds separated by 100 milliseconds could completely ablate prostate cancer cells without inducing thermal damage.
CONCLUSIONS: Irreversible electroporation represents a new nonthermal ablation modality. This study has produced values for prostate cancer treatment with irreversible electroporation.

Entities:  

Mesh:

Year:  2008        PMID: 18951581     DOI: 10.1016/j.juro.2008.08.003

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  39 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

2.  Real-time ultrasound imaging of irreversible electroporation in a porcine liver model adequately characterizes the zone of cellular necrosis.

Authors:  Carl R Schmidt; Peter Shires; Mary Mootoo
Journal:  HPB (Oxford)       Date:  2011-11-16       Impact factor: 3.647

Review 3.  Ablative Therapies for the Treatment of Small Renal Masses: a Review of Different Modalities and Outcomes.

Authors:  Nicholas Kavoussi; Noah Canvasser; Jeffrey Caddedu
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

4.  The influence of skeletal muscle anisotropy on electroporation: in vivo study and numerical modeling.

Authors:  Selma Corović; Anze Zupanic; Simona Kranjc; Bassim Al Sakere; Anne Leroy-Willig; Lluis M Mir; Damijan Miklavcic
Journal:  Med Biol Eng Comput       Date:  2010-04-28       Impact factor: 2.602

5.  Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones.

Authors:  Yang Guo; Yue Zhang; Grace M Nijm; Alan V Sahakian; Guang-Yu Yang; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2010-12-03       Impact factor: 11.105

6.  A statistical model for multidimensional irreversible electroporation cell death in tissue.

Authors:  Alex Golberg; Boris Rubinsky
Journal:  Biomed Eng Online       Date:  2010-02-26       Impact factor: 2.819

7.  Recent advances in focal therapy of prostate and kidney cancer.

Authors:  Matvey Tsivian; Thomas J Polascik
Journal:  F1000 Med Rep       Date:  2010-01-18

8.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 9.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

10.  An e-learning application on electrochemotherapy.

Authors:  Selma Corovic; Janez Bester; Damijan Miklavcic
Journal:  Biomed Eng Online       Date:  2009-10-20       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.